Brain Tumor News!


Note: The comments under each article title are the opinion of our president, Al Musella, DPM,
and do not reflect official policy of the Musella Foundation!
Displaying Stories 2530 to 2549 of 7,806
Previous 20           Next 20


12/11/12 IBTA E News December 2012        

 This is from our friends at the IBTA!



12/05/12 Peregrine Shows Desperation in Dusting Off Ancient Brain Tumor Drug        

 This is an interesting treatment. Cotara is a monoclonal antibody against the parts of a cell that are exposed when they are dying - combined with a radioactive Iodine.  The hallmark of glioblastomas is necrosis - which seems to make this an ideal target for Cotara.

 This article is scathingly against the company that i developing this treatment.  Don't worry about that nonsense.  The author has no knowledge of the science involved - he is just worried about money.  What he missed was that 10 years ago, the technology to deliver treatments like this using CED (Convection enhanced delivery) was just being developed. Typically less than half of the patients would get the drug to the right location.  And this was with the best surgeons in the USA.  In India - forget about it.

I think that we are now at the point where CED can hit the target consistently - at least 90% of the time, and will get better with the experiance of the surgeon. That alone should greatly increase the chances of this treatments' success!  The trial should be open soon. I think it is worth considering.



12/04/12 Protracted low doses of temozolomide for the treatment of patients with recurrent glioblastoma: A phase II study.        

 This article says that the every other week schedule of low dose Temodar did not work for recurrent glioblastomas who failed the standard schedule of Temodar.  



12/03/12 Advancing “Breakthrough” Drug Therapies        

Looks like the FDA finally understands what we are going through.  It kills me that treatments that are looking great in clinical trials have to wait years to become available.  Especially things that are relatively harmless and are used in addition to the standard treatment, such as the vaccines (CDX-110, DC-VAX and ICT-107 are the front runners and there are a few more vaccines), as well as 5-ALA - the dye that lights up brain tumors so the surgeon can get more out. We need to help the companies that make these drugs get "breakthrough" status..  



11/30/12 City MD sues radiologists over tumour, brain damage        

 I usually don't publish stories about lawsuits but this brings up an important point:  When you are told the scan is "stable" that usually means that there is less than about 25% growth or shrinkage.  If you have a string of 4 "stable" scans in a row, and each one actually had 24% growth, you could have a tumor double in size and still be called stable.  It is imperative to go back to the original post-op or post-radiation scan and compare that to the current scan.



11/30/12 RTK inhibition: looking for the right pathways toward a miracle.        

 This is theoretical but I love the thought process.. this researcher thinks he knows why Avastin sometimes fails - and thinks he may have a way to block the failure.  He did not try it yet - just thinking about it. We (the Musella Foundation) have funded 2 similiar projects - looking at drugs to add to Avastin to make it work better.  The first one failed to show a benefit, but the second one is still ongoing.  I think this concept is the way to a big breakthrough. We just need to find the right combination.



11/30/12 Effectiveness of the bevacizumab-irinotecan regimen in the treatment of recurrent glioblastoma multiforme: Comparison with other second-line treatments without this regimen.        

 This talks about the combination of Avastin and CPT-11 for recurrent glioblastoma.  They compared patients who took this combination with patients who did all other available treatments and this group did better by 7 months (70%).   Previous similiar studies showed a similiar benefit but when avastin alone was tested with avastin + CPT-11, the results were pretty close - the avastin + CPT-11 group did a little better but had more side effects. Not clear which is best yet.



11/30/12 Swedish Receives $2.5 Million Grant from the Ivy Foundation to Advance Brain Cancer Research        

 Major grant from the Ivy Foundation to one of my favorite brain tumor doctors.. Dr. Greg Foltz.   He was a speaker at one of our conferences.  You can see his lecture at: virtualtrials.com/VIDEO2010.cfm

    He is working on finding drugs that are already FDA approved for other conditions that might also help brain tumors.  Great approach!



11/30/12 Correction: video name is: Bringing Light Please vote!        

 I sent this out yesterday and didn't say the name of the video.. sorry!



11/29/12 Short film about Tumor Paint! Please vote for it!        

 One of my friends, Dr Jim Olson, invented a drug that lights up the tumor so the surgeon can see where the tumor is during surgery.  This short film explains why it is so important.  The film is up for an award that can help raise money to get the drug developed!  Please vote for it!  



11/28/12 The Florida Brain Tumor Association (FBTA) is hosting their yearly conference, " Progress Against Brain Tumors" , Feb. 9, 2013.        

 This organization always puts on an excellent conference. Very worthwhile to go!



11/28/12 'Tumor Paint' Research Of Pediatric Oncologist Jim Olson Featured In Short Film -- A Sundance Festival Semifinalist        

This is an amazing technology..  it allows the surgeon to see where the tumor is during surgery. This video shows why it is so important.    The video is in a contest. Winner gets $100,000 which will be used to help develop this tumor paint.  We need you to vote for it. To vote, go to: http://vimeo.com/focusforwardfilms/semifinalists  and click on the tumor pain video, then when viewing the video, click the VOTE icon on the middle right side of the video, then confirm it!

(Disclaimer: Dr Olson is a friend of mine:)



11/25/12 Trabectedin has promising antineoplastic activity in high-grade meningioma.        

 Way too early - and had significant side effects in the 1 person they tried it on, but may be an option for people with high grade meningioma who run out of other options.  It is available off label now under the brand name Yondelis



11/21/12 Uninsured brain cancer patients may be more likely than insured to die after surgery to remove tumor        

They also found that medicaid patients do as well as patients with private insurance. Uninsured patients are twice as likely to die in the hospital.  They did not figure out why - but that has to be looked at.



11/21/12 Diffusion Pharmaceuticals Successfully Completes Phase I Brain Cancer Trial        

They are testing a new treatment for GBMs: trans sodium crocetinate . This drug increases the oxygenation of the tumor and is thought that it may sensitize the tumor to radiation and chemotherapy. It worked well in the lab. They tried it on a small group of GBM patients to test for safety and apparently it is safe enough to go ahead to a larger trial to see if it works.



11/20/12 New Fundraiser - doesn't cost you anything - please participate!        

 I really need help with this fundraiser..  It is simple, and doesn't cost you anything:  There has been a huge settlement in a class action lawsuit.  Most people are eligible, but each person gets only a small settlement.  However, if we get a lot of people to donate their claim to the Musella Foundation, it can become significant enough to fund a brain tumor research project!

You just fill out a form on a website to donate your  claim to the Musella Foundation.  No receipts are needed. Takes very little time.

Please pass this along to all of your friends and ask them to participate and to send it to thier friends.  They have to be in by Dec 6, 2012.  We only have a few weeks!



11/19/12 Genentech Study Showed That Avastin Helped People with Newly Diagnosed Glioblastoma Live Longer with        

 This was the big news at the Society of Neuro-oncology conference this weekend.  There was about a 50% improvement in progression free survival by adding Avastin to the standard treatment, over using the standard treatment alone.  This means that patients feel better and can take care of themeselves longer with Avastin than without.  

 However, the question remains when is the best time to use Avastin, right at the start or wait for recurrence. That question is not yet answered.   There seems to be (but hasn't been tested yet) about the same time benefit for using at it the time of recurrence rather than at the start.  (Although using it at the start allowed patients to functional at the highest level for a longer period of time. )  My own thoughts (and I am not an MD - so take it for what it is worth):  My preference would be to enter a clinical trial for newly diagnosed GBM patients and hold off on the Avastin until the time of recurrence. IF you can not enter a trial, then it is a toss-up on when the best time to start Avastin would be. Either way can be argued.  There are more trials (such as the Tocagen trial) that now allow you to enter after having had Avastin, so that removes one of the barriers to using Avastin upfront.

Disclosure: Genetech is a sponsor of the Musella Foundation



11/13/12 Long-term survival of patients suffering from glioblastoma multiforme treated with tumortreating fields.        

 This article reports long term results of the first Novocure TTF device trial:  4 out of 20 patients GBM (20%) alive, in good health and no longer receiving any treatment with no clinical or radiological signs of recurrence more than 7 YEARS after starting the trial! (2 were newly diagnosed, 2 were recurrent when they started the trial).

This is amazing. The expected 7 year survival rate is about 4%, so you would expect less than 1 of the original 20 patients to survie. This is 500% better.  

Disclaimer: The company that makes the Novocure TTF device is a sponsor of our organization.



11/13/12 Avastin Reduces Brain Necrosis from Radiation        

 This is an exciting article.. it says that using Avastin in combination with stereotactic radiosurgery greatly reduces the chances of developing radiation necrosis from 50% to 3-6%, and almost doubles the average survival!

Disclaimer: Genetech - the makers of Avastin - are a sponsor of our organization! 



11/13/12 Voices Against Brain Cancer to Host Annual "Join the Voices! Run/Walk" in Partnership with New York Road Runners        

"Voices Against Brain Cancer" has been working with us (the Musella Foundation) to get great projects funded!  Please support this event if you are in the NY area!



Displaying Stories 2530 to 2549 of 7806
Previous 20           Next 20